These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235 [TBL] [Abstract][Full Text] [Related]
4. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Witzig TE; Reeder CB; LaPlant BR; Gupta M; Johnston PB; Micallef IN; Porrata LF; Ansell SM; Colgan JP; Jacobsen ED; Ghobrial IM; Habermann TM Leukemia; 2011 Feb; 25(2):341-7. PubMed ID: 21135857 [TBL] [Abstract][Full Text] [Related]
7. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Tobinai K; Ogura M; Maruyama D; Uchida T; Uike N; Choi I; Ishizawa K; Itoh K; Ando K; Taniwaki M; Shimada N; Kobayashi K Int J Hematol; 2010 Nov; 92(4):563-70. PubMed ID: 20972652 [TBL] [Abstract][Full Text] [Related]
9. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327 [TBL] [Abstract][Full Text] [Related]
10. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539 [TBL] [Abstract][Full Text] [Related]
11. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Ansell SM; Tang H; Kurtin PJ; Koenig PA; Inwards DJ; Shah K; Ziesmer SC; Feldman AL; Rao R; Gupta M; Erlichman C; Witzig TE Lancet Oncol; 2011 Apr; 12(4):361-8. PubMed ID: 21440503 [TBL] [Abstract][Full Text] [Related]
12. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512 [TBL] [Abstract][Full Text] [Related]